Last reviewed · How we verify
Amlodipine, Levamlodipine
At a glance
| Generic name | Amlodipine, Levamlodipine |
|---|---|
| Also known as | NORVASC®, Xuanning® |
| Sponsor | Conjupro Biotherapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients (PHASE3)
- Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B (PHASE1)
- An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
- S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
- A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome (PHASE4)
- Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects (PHASE1)
- Anti Inflammatory Treatment of Hypertension (PHASE2, PHASE3)
- Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine, Levamlodipine CI brief — competitive landscape report
- Amlodipine, Levamlodipine updates RSS · CI watch RSS
- Conjupro Biotherapeutics, Inc. portfolio CI